Is the incidence and prevalence of inhibitors greater with recombinant products? No

This publication has 14 references indexed in Scilit:

• Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation
  Journal of Thrombosis and Haemostasis, 2004
• The safety and efficacy of B‐domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A
  Haemophilia, 2003
• Genetic Basis of Inhibitor Development in Severe Haemophilia A and B
  Published by Wiley ,2002
• Sucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy
  Thrombosis and Haemostasis, 2000
• Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentrates
  Haemophilia, 1999
• Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964-97
  British Journal of Haematology, 1999
• Human recombinant DNA‐derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5‐year study of home therapy
  Haemophilia, 1999
• Utilization of Previously Treated Patients (PTPs), Noninfected Patients (NIPs), and Previously Untreated Patients (PUPs) in the Evaluation of New Factor VIII and Factor IX Concentrates
  Thrombosis and Haemostasis, 1999
• Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
  The Lancet, 1992
• Acquired Circulating Anticoagulants in Hemophilia A
  New England Journal of Medicine, 1969